Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Innate Immunity Bioassays

Our industry-leading suite of innate immunity bioassays is a critical tool in the development of immunotherapy drugs and can help accelerate your drug development process.

With our extensive collection of assays, you can quickly and accurately screen and characterize antibodies and small molecules to determine potency and stability, ensuring lot release meets rigorous QC standards.

Our bioassays are versatile and can be used in a range of settings, making them an essential tool for any immunotherapy drug development program.

Filter By

Innate Immunity

Showing 4 of 4 Products

What are Innate Immunity Bioassays?

Innate immunity is the first line of defense in the human body against invading pathogens. It is a nonspecific immune response that is immediately activated upon the detection of "non-self" such as viruses, bacteria and cancerous cells. The innate immune system involves a complex interplay of cellular and molecular mechanisms that work together to identify and eliminate those aberrant cells.

Key players in innate immunity include macrophages, which are phagocytic cells that engulf and digest foreign invaders, and Toll-like receptors (TLR), which are specialized proteins that recognize and respond to different types of pathogenic or tumor-associated molecules. Additionally, antibody-dependent cellular phagocytosis (ADCP) involves the binding of antibodies to pathogens or tumors and then activating macrophages to engulf and destroy them.

Lastly, an important aspect of innate immunity involves the recognition of "self" molecules through the interaction of proteins like SIRPα and CD47 or ILT4(LILRB2) with "self" signals on healthy cells, preventing macrophages from mistakenly attacking them.

Biologic therapeutics are in the clinic to modulate these mechanisms of action as a promising strategy for cancer immunotherapy. Cell-based reporter bioassays are critical tools to quantify the activity of these molecules for ranking, potency and stability purposes.